Viking Therapeutics to Present Metabolic Innovations at September Investor Conferences
- Viking Therapeutics will present its metabolic therapies at investor conferences in September, including fireside chats.
- The company is focusing on VK2735, a dual agonist in Phase 3 trials for obesity treatment.
- Viking is also developing an oral formulation of VK2735 and advancing VK2809 for thyroid health.
Viking Therapeutics to Showcase Innovative Metabolic Therapies at Upcoming Conferences
Viking Therapeutics, Inc. is poised to highlight its advancements in metabolic and endocrine disorder therapies at several important investor conferences this September. The company, which specializes in developing innovative treatments, will participate in the Cantor Global Healthcare Conference from September 3 to 5, where it is scheduled for a fireside chat on September 5 at 9:45 a.m. Eastern in New York City. Shortly after, Viking will take part in the Morgan Stanley 23rd Annual Global Healthcare Conference from September 8 to 10, with a fireside chat on September 8 at 3:20 p.m. Eastern, available via webcast. These events represent a significant platform for Viking to engage with investors and showcase its clinical developments.
As Viking continues to make strides in its clinical programs, a key focus is on VK2735, a dual agonist that targets GLP-1 and GIP receptors. This innovative therapy is currently being evaluated in a Phase 3 obesity program, which encompasses the VANQUISH-1 and VANQUISH-2 trials. These trials follow promising results from earlier Phase 1 and Phase 2 studies, indicating the potential of VK2735 to address metabolic disorders effectively. The emphasis on such advanced clinical trials exemplifies Viking's commitment to developing therapies that can significantly impact the lives of individuals suffering from obesity and related conditions.
In addition to VK2735, Viking is also exploring an oral formulation of this dual agonist in a Phase 2 trial, reflecting its dedication to expanding treatment options for patients. The company is simultaneously advancing VK2809, an oral small molecule designed as a selective thyroid hormone receptor beta agonist. These dual tracks of development underscore Viking's strategic focus on innovative therapeutics that target critical pathways in metabolic health.
Alongside its conference participation, Viking plans to make webcasts of the Morgan Stanley and Bernstein events available on its website, ensuring that a broader audience can access its updates and insights. This approach not only enhances transparency but also reinforces Viking's commitment to engaging with the investment community as it advances its pioneering research and development efforts.
